Heparin Market To Reach $12.1 Billion by 2035

Heparin market size was valued at $8.5 billion in 2025 and is projected to reach $12.1 billion by 2035, growing at a CAGR of 3.8% during 2026–2035. Growth in this market is primarily driven by the rising global burden of cardiovascular diseases and thrombotic disorders, which significantly increase the demand for anticoagulants such as heparin across hospitals and clinical settings.

Browse the full report description of “Heparin Market Size, Share & Trends Analysis Report, By Product Type (Unfractionated Heparin, Low Molecular Weight Heparin, Ultra-Low Molecular Weight Heparin), By Application (VTE, Atrial Fibrillation, CAD/MI, Hemodialysis, Surgical Procedures), By End User (Hospitals, ASCs, Dialysis Centers, Specialty Clinics), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/heparin-market

A key macro driver influencing the market is the increasing prevalence of cardiovascular diseases. According to the World Health Organization, cardiovascular diseases account for 17.9 million deaths annually, representing approximately 32% of all global deaths. This has led to a surge in demand for anticoagulants, particularly for managing conditions such as venous thromboembolism (VTE), atrial fibrillation, and myocardial infarction. Additionally, data from the Organisation for Economic Co-operation and Development indicates that hospital admission rates for cardiovascular treatments and surgeries continue to rise across developed economies, further supporting the consistent utilization of heparin in surgical and post-operative care.

Among product types, Low Molecular Weight Heparin (LMWH) is the fastest-growing segment due to its predictable pharmacokinetics, ease of administration, and reduced need for monitoring compared to unfractionated heparin. LMWH is widely used in outpatient settings and for long-term anticoagulation therapy, making it highly preferred across hospitals and ambulatory surgical centers. The segment’s growth is also supported by increasing adoption in dialysis procedures and minimally invasive surgeries.

Key market players are actively adopting strategic initiatives to strengthen their market position and expand their global footprint. In January 2024, Sanofi S.A. expanded its production capacity for enoxaparin to meet rising global demand. In March 2023, Pfizer Inc. enhanced its sterile injectable manufacturing capabilities, improving supply chain efficiency for anticoagulant products. In July 2022, Teva Pharmaceutical Industries Ltd. launched a generic version of enoxaparin in additional markets, strengthening its LMWH portfolio.

Recent Developments

• In July 2025, B. Braun Medical Inc. (B. Braun) launched new Heparin Sodium Injections into the US market, expanding its portfolio to include 25,000 Units Heparin in 0.45% Sodium Chloride Injection (50 units/mL) and 25,000 Units Heparin in 0.45% Sodium Chloride Injection (100 units/mL). 
• In August 2023, Aspen Pharmacare Holdings Limited entered a strategic partnership with Lilly to enhance injectable anticoagulant distribution across emerging markets.
• In March 2023, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced the expansion of its heparin API production facilities to secure upstream supply.

Market Coverage

• The market number available for – 2025-2035
  • Base year- 2025
  • Forecast period- 2026-2035
• Segment Covered-
  o By Product Type
  o By Application
  o By End User

Competitive Landscape Pfizer Inc.; Sanofi S.A.; Shenzhen Hepalink Pharmaceutical Group Co., Ltd.; Aspen Pharmacare Holdings Limited; Teva Pharmaceutical Industries Ltd.

Key questions addressed by the report.

• What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • Who is the leader in the market?
  • How are players addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Heparin Market Report Segment

1. By Product Type

• Unfractionated Heparin (UFH)
  • Low Molecular Weight Heparin (LMWH)
  • Ultra-Low Molecular Weight Heparin (ULMWH)

2. By Application

• Venous Thromboembolism (VTE)
  • Atrial Fibrillation
  • Coronary Artery Disease / Myocardial Infarction
  • Hemodialysis
  • Surgical Procedures

3. By End User

• Hospitals
  • Ambulatory Surgical Centers (ASCs)
  • Dialysis Centers
  • Specialty Clinics

Global Heparin Market Report Segment by Region

North America

• United States
  • Canada

Europe

• UK
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe

Asia-Pacific

• China
  • India
  • Japan
  • South Korea
  • Australia and New Zealand
  • ASEAN Economies
  • Rest of Asia-Pacific

Rest of the World

• Latin America
  • Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/heparin-market